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Introduction
============

Tracheal extubation following general anesthesia is associated with hemodynamic changes and airway reflexes \[[@REF1]\]. The goals of smooth extubation are to avoid hemodynamic changes, minimize airway stimulation, and prevent straining, coughing, breath-holding, and laryngospasm, as well as to ensure continuous oxygen delivery to the lungs. Patients with cardiovascular and/or neurological diseases, active and passive smokers, and those with chronic airway diseases have a higher incidence of complications as related to extubation \[[@REF1]\].

Several drugs have been investigated to obtund the hemodynamic extubation response in vulnerable patients. These are narcotics \[[@REF2]-[@REF3]\], local anesthetics \[[@REF4]\], calcium channel blockers \[[@REF5]\], alpha agonists, and so on \[[@REF6]-[@REF7]\]. All these pharmacological interventions are associated with certain undesirable side effects \[[@REF4]\].

The rationale of this systematic review was to determine the effectiveness of the pharmacological agents administered for attenuating the hemodynamic extubation response with minimal effects on the quality of tracheal extubation.

Objectives

Our primary objective was to evaluate the effect of pharmacological agents administered for attenuating the tracheal extubation response on the quality of extubation as judged by the presence or absence of cough and/or sedation and the presence of laryngospasm/bronchospasm in adult patients undergoing general anesthesia. Our secondary objective was to evaluate the effect of these drugs on other, immediate post-extubation complications such as respiratory depression, desaturation, bradycardia, hypotension, and nausea and vomiting.

Materials and methods
=====================

Design

A systematic review of randomized controlled trials (RCTs) with a meta-analysis.

Data sources

The Medical Literature Analysis and Retrieval System Online (MEDLINE), Cumulative Index of Nursing and Allied Health Literature (CINAHL), and Cochrane Central Register of Controlled Trials (CENTRAL) databases were systematically searched for articles published between January 1, 1990, and December 31, 2015 (26 years).

The search strategy used and the keywords are provided in the appendix.

A bibliography of relevant articles was searched for additional studies and the search was not restricted by language. Authors of identified publications were not contacted for additional information.

Eligibility criteria

Inclusion Criteria

We included RCTs that studied the effect of pharmacological agents on both the hemodynamic extubation response as well as the quality of extubation. RCTs with both placebo and a drug control group, reporting on adult patients (18 years or above), of any race, either gender, and undergoing elective surgery in the operating room were included.

Studies that reported on any of the following primary or secondary outcomes were included.

Primary outcomes: The primary outcome was the quality of extubation. This was assessed by the presence or absence of cough at the time of extubation (graded from 1 to 5) \[[@REF8]\], degree of sedation after extubation (Ramsay scale score of 1 and 2 meaning no sedation) \[[@REF9]-[@REF10]\], and the presence of laryngospasm/ bronchospasm at the time of extubation.

Secondary outcomes: The secondary outcome were respiratory depression (respiratory rate less than 10 breaths per minute), bradycardia (heart rate less than 60 beats per minute), hypotension (blood pressure less than 20% from the baseline), nausea and vomiting, desaturation (peripheral capillary oxygen saturation (SpO2) less than 92%) and any other adverse effects of drugs used for the suppression of the hemodynamic extubation response.

Exclusion Criteria

Studies where different doses of routine anesthetic drugs were used, (induction agents, muscle relaxants or inhalation agents) for attenuating the hemodynamic response to extubation were excluded.

Studies of patients undergoing tracheal extubation outside the operating room were also excluded.

Screening and Study Eligibility

All abstracts were independently screened by two reviewers. The selected articles were again reviewed independently by two reviewers. Any disagreement was referred to the third reviewer. The reasons for the exclusion of studies were also noted.

Data extraction and handling

Data were extracted individually by two reviewers on a predesigned data extraction form.

Assessment of Risk of Bias in Individual Studies

The risk of bias assessment was noted appropriately by the authors according to a standard description for each type of bias based on the Cochrane risk of bias tool \[[@REF11]\]. Random sequence generation (selection bias), allocation concealment (selection bias), blinding of participants (performance bias), blinding of outcome assessment (detection bias), bias of incomplete outcome data (attrition bias), and selective reporting bias (reporting bias) were assessed. After an independent assessment and then comparison, any conflicts were resolved by a discussion with the third reviewer. The studies were categorized into good quality, fair quality, and poor quality according to the thresholds set for converting the Cochrane risk of bias tool to Agency for Health Care Research and Quality (AHRQ) standards \[[@REF11]\].

Statistical analysis 

Meta-analyses were performed using Review Manager, version 5 software (The Cochrane Collaboration, Oxford, UK). The rate of cough, hypotension, bradycardia and nausea/vomiting of the intervention and control groups were tabulated and presented graphically using forest plots. The Mantel-Haenszel (M-H) analysis method with the random-effects model was used to compute the effect size in terms of the odds ratio for dichotomous outcomes. The chi-square (π2) test and I2 were performed to observe variability in the intervention effect that was due to heterogeneity among studies.

Results
=======

Study selection

Our literature search identified 33 abstracts through both a database and a manual search. After going through the full texts of the abstracts, nine were excluded, as they did not fulfill our inclusion criteria completely, hence, 24 studies were included in the qualitative analysis (Figure [1](#FIG1){ref-type="fig"}).
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The data of all the study characteristics are shown in Table [1](#TAB1){ref-type="table"}.

###### Characteristics of included studies

IV: intravenous; TCM: transcricoid membrane; N/S: normal saline; n: group sample size; N: total sample size; min: minutes

  -------------------------------- ----- ------------------------------- --------------------------- --------------- ------------------------- -------------------------------
  Author/ Year                      N    Study Groups                    Dose                        Per Group (n)   Route of Administration   Timing
  Nishina 1995 \[[@REF2]\]         60    Saline                                                      20              Bolus                     At time of peritoneal closure
                                         Fentanyl                        1 ug/kg                     20                                         
                                         Fentanyl                        2 ug/kg                     20                                         
  Aksu 2009 \[[@REF3]\]            40    Dexmedetomidine                 0.5 ug/kg                   20              Infusion                  Before extubation
                                         Fentanyl                        1 ug/kg                     20                                         
  Mistry 2016 \[[@REF5]\]          30    Verapamil                       0.1mg/kg                    15              IV Bolus/Infusion         On return of breathing
                                         Dexmedetomidine                 0.3ug/kg                    15                                         
  Kim 2015 \[[@REF6]\]             115   Saline                          0.1 ml/kg/hr                28(a), 30(b)    Infusion                  Drug given after induction
                                         Dexmedetomidine                 0.4 ug/kg/hr                27(a), 30(b)    Infusion                   
                                         Lidocaine                       1mg/kg                      25              I.V Bolus/Infusion         
                                         PG.E                            0.1/mg/kg                   25              Infusion                   
                                         PG.L                            0.1/mg/kg                   25              Bolus + Infusion           
  Xiaochun 2014 \[[@REF7]\]        90    Saline                                                      30              IV Bolus                  30 minutes after intubation
                                         Dexmedetomidine                 0.4 ug/kg                   30              IV Bolus                   
                                         Dexmedetomidine                 0.8 ug/kg                   30              IV Bolus                   
  Mikawa 1996 \[[@REF12]\]         80    Saline                                                      20              I.V/ Bolus                3 min after reversal
                                         Diltiazem                       0.2 mg/kg                   20                                         
                                         Verapamil                       0.5 mg/kg                   20                                         
                                         Verapamil                       0.1 mg/kg                   20                                         
  Nishina 1997 \[[@REF13]\]        100   Saline                          1mg/kg                      25              I.V                       2 min before extubation
                                         Lidocaine                       1mg/kg                      25              I.V Bolus/Infusion         
                                         PG.E                            0.1/mg/kg                   25              Infusion                   
                                         PG.L                            0.1/mg/kg                   25              Bolus + Infusion           
  Jee 2002 \[[@REF14]\]            75    Control                                                     25              IV Bolus                  3 to 5 min before extubation
                                         Lidocaine                       1 mg/kg 2 %                 25              IV Bolus                   
                                         Lidocaine                       1 mg/kg 2 %                 25              Intra tracheally           
  Guler 2005 \[[@REF15]\]          60    Dexmedetomidine                 0.5mg/kg                    30              I.V bolus                 5 min before end of surgery
                                         Saline                                                      30                                         
  Mahoori 2014 \[[@REF16]\]        50    Saline                                                      25              Bolus                     90 sec prior to extubation
                                         Remifentanil                    0.2 ug/kg                   25              Bolus                      
  Andrzejowski 2002 \[[@REF17]\]   40    Saline                          5ml                         20              Tube cuff                 Insertion of first skin clip
                                         Lidocaine                       2% 5ml                      20              Tube cuff                  
  Lee 2014 \[[@REF18]\]            142   Saline                                                      71              Infusion                  After extubation
                                         Dexmedetomidine                 0.5 ug/kg                   71              Infusion                   
  Shajar 1999 \[[@REF19]\]         40    Saline                                                      20              I.V/ Bolus                At time of last suture
                                         Remifentanil                    1 ug/kg                     20                                         
  Moustafa 2012 \[[@REF20]\]       60    Lidocaine                       1.0mg/kg                    20              Bolus                     5 min before extubation
                                         Dexmedetomidine                 1 mg/kg                     20                                         
                                         Dexa +Lidocaine                 0.1 ug/kg + 1 mg/kg         20                                         
  Nho 2009 \[[@REF21]\]            40    Saline                                                      20              Infusion                  4 min post extubation
                                         Remifentanil                                                20                                         
  Aouad 2009 \[[@REF22]\]          60    Saline                                                      30              Infusion                  At the end of the surgery
                                         Remifentanil                    1/10^th ^dose of infusion   30              Infusion                   
  Qing Fan 2015 \[[@REF23]\]       74    Sevoflurane-Remifentanil        0.03 ug/kg/min              25              Infusion                  10 min before extubation
                                         Sevoflurane-Dexmedetomide SD5   0.5 ug/kg                   24                                         
                                         Sevoflurane​​​​​​​-SD7          0.7 ug/kg                   25                                         
  Dutta 2016 \[[@REF24]\]          45    Saline                          10 ml                       15              Endotracheally            After last skin suture
                                         Lidocaine                       1.5 mg/kg                   15              Endotracheally             
                                         Dexmedetomidine                 0.3 ug/kg                   15              IV                         
  Turan2008 \[[@REF25]\]           40    Saline                                                      20              Bolus over 60 second      5 min before end of procedure
                                         Dexmedetomidine                 0.5 ug/kg                   20              Bolus over 60 second       
  Sharma 2014 \[[@REF26]\]         60    Saline                          10 ml                       20              Bolus                     Just before extubation
                                         Lidocaine                       1.5 mg/kg                   20              Bolus                      
                                         Dexmedetomidine                 0.5 ug/kg                   20              Bolus                      
  Gao 2014 \[[@REF27]\]            70    Ropivaciane                     20mg                        35              TCM                       Before intubation
                                         Diacine                         20mg                        35              TCM                        
  Kothari 2014 \[[@REF28]\]        50    Dexmedetomidine                 0.5 ug/kg                   25              IV bolus                  5 minutes before extubation
                                         Lignocaine                      1.5 mg/kg                   25                                         
  Bindu 2013 \[[@REF29]\]          50    Saline                          100 ml                      25              I.V infusion              15 min before extubation
                                         Dexmedetomidine                 0.75 mcg/kg                 25              I.V infusion               
  Shruthi 2016 \[[@REF30]\]        80    Saline                          10 ml                       40              Infusion                  Beginning of skin closure
                                         Dexmedetomidine                 0.5 ug/kg                   40              Infusion                   
  -------------------------------- ----- ------------------------------- --------------------------- --------------- ------------------------- -------------------------------

Hemodynamic changes

The hemodynamic response was reported as blood pressure (BP) and heart rate (HR) change in all trials but the manner of reporting was different among studies. Nine studies documented a change in systolic blood pressure (SBP), diastolic blood pressure (DBP), and HR \[[@REF2]-[@REF3],[@REF7],[@REF12]-[@REF17]\] while 12 studies documented the changes in mean arterial pressure (MAP) and HR only \[[@REF5]-[@REF6],[@REF18]-[@REF27]\]. Three studies documented changes in MAP in addition to SBP, DBP, and HR \[[@REF28]-[@REF30]\]. A saline control group was used in 18 studies \[[@REF2],[@REF6]-[@REF7],[@REF12]-[@REF19],[@REF21]-[@REF22],[@REF24]-[@REF26],[@REF29]-[@REF30]\]. In four studies, no placebo was used in the control against the study drug \[[@REF3],[@REF20],[@REF27]-[@REF28]\]. In seven studies, the authors compared two different drugs or the same drug in different doses \[[@REF3],[@REF5],[@REF12],[@REF20],[@REF23],[@REF27]-[@REF28]\].

Hypotension was recorded in three studies \[[@REF15],[@REF29]-[@REF30]\] while bradycardia was observed in seven studies (see Table [2](#TAB2){ref-type="table"}) \[[@REF3],[@REF5],[@REF15],[@REF18],[@REF26],[@REF29]-[@REF30]\].

###### Attenuation of hemodynamic response in the included studies

HR: heart rate; SBP: systolic blood pressure; DBP: diastolic blood pressure; MAP: mean arterial pressure

  -------------------------------- -------------------------------------- --------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study ID Year                    Attenuation of Haemodynamic Response   Drug Groups                             Comments
  Nishina 1995 \[[@REF2]\]         Yes                                    Fentanyl Saline                         HR, SBP, DBP higher in the control group as compared to fentanyl (p\<0.05)
  Mikawa 1996 \[[@REF12]\]         Yes                                    Diltiazem, Verapamil, Saline            HR, SBP, DBP. Both drugs attenuated but verapamil 0.1 mg /kg more effective
  Nishina 1997 \[[@REF13]\]        Yes                                    Lidocaine, PGE, PGE, Lidocaine Saline   PGE, Lidocaine combination attenuated SBP, DBP, and HR (p\<0.05)
  Shajar 1997 \[[@REF19]\]         Yes                                    Remifentanil Saline                     Remi attenuated both MAP, HR in comparison with saline (p\<0.01 and 0.05)
  Jee 2002 \[[@REF14]\]            Yes                                    Lidocaine Saline                        HR, SBP, DBP were attenuated by Lidocaine sprayed down the ETT immediately after extubation only
  Andrzejowski 2002 \[[@REF17]\]   No difference                          Lidocaine Saline                        No difference between the groups (p\>0.05)
  Guler 2005 \[[@REF15]\]          Yes                                    Dex Saline                              SAP and DAP were significantly lower in the dex group compared to saline (p\<0.05). Episode of bradycardia in 1 and hypotension in 3 patients in the dex group
  Turan 2008 \[[@REF25]\]          Yes                                    Dex Saline                              HR and MAP were significantly higher in control as compared to the dex group (p\<0.01)
  Aouad 2009 \[[@REF22]\]          Yes                                    Remifentanil Saline                     HR and MAP increased in control as compared to remi (p\<0.05)
  Nho 2009 \[[@REF21]\]            Yes                                    Remifentanil Saline                     HR and MAP were significantly increased in the control group as compared to remi (HR p=0.001 and MAP p=0.002)
  Aksu 2009 \[[@REF3]\]            Yes                                    Dex Fentanyl                            HR, SBP, DBP were significantly increased by in fentanyl group as compared to dex (HR p=0.003and SBP p=0.037)
  Moustafa 2012 \[[@REF20]\]       Yes                                    Lidocaine Dex Dex plus lidocaine        Dex+lidocaine combination attenuated HR, MAP, RPP in comparison to the two drugs alone (p\<0.05)
  Bindhu 2013 \[[@REF29]\]         Yes                                    Dex Saline                              HR, SBP, DBP, and MAP significantly higher in control (p\<0.05). Bradycardia and hypotension reported with dex
  Mahoori 2014 \[[@REF16]\]        Yes                                    Dex Saline                              HR, SBP, DBP were significantly increased in control (p\<0.05)
  Xiachun^7^ 2014 \[[@REF7]\]      Yes                                    Dex Saline                              Dexmedetomidine 0.8 ug/kg more effectively attenuated HR, SBP, and DBP
  Sharma 2014 \[[@REF26]\]         Yes                                    Dex Lidocaine Saline                    Dexmedetomidine more effective than lignocaine in attenuating HR (p=0.01), MAP. One patient had bradycardia in the dex group
  Lee 2014 \[[@REF18]\]            Yes                                    Dex Saline                              HR, MAP were attenuated in the dex group as compared to control. One patient had bradycardia in the dex group
  Kothari 2014 \[[@REF28]\]        Yes                                    Dex Lidocaine                           HR, SBP, DBP, MAP were below baseline in the dex group as compared to the lido group (p\<0.05)
  Gao 2014 \[[@REF27]\]            Yes                                    Ropivacaine Diacine                     HR, MAP Ropivaciane more effective than diacine ( p\<0.05)
  Fan 2015 \[[@REF23]\]            Yes                                    Remifentanil Dex                        HR, MAP. Dexmedetomidine more effective than remifentanil (p\<0.05)
  Kim^6^ 2015 \[[@REF6]\]          Yes                                    Dex Saline                              HR was lower in the dex group (p\<0.05), no difference in MAP
  Mistry 2016 \[[@REF5]\]          Yes                                    Verapamil Dex                           HR, MAP were higher in the verapamil group than in the dex but statistically insignificant
  Shruthi 2016c\[[@REF30]\]        Yes                                    Dex Saline                              HR, SBP, DBP, MAP were lower in the dex group but significantly increased in the control (p\<0.001)
  Dutta^24^ 2016 \[[@REF24]\]      Yes                                    Lidocaine Dex Saline                    HR, MAP. Dexmedetomidine better effect than lignocaine spray (p\<0.05)
  -------------------------------- -------------------------------------- --------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------

Surrogate measures used for the quality of extubation and the immediate post-extubation complications

The following outcome measures were used for assessing the quality of extubation and the immediate post-extubation complications. The primary outcome measures were cough, sedation, and laryngospasm/bronchospasm. The secondary outcome measures seen were hypotension, bradycardia, and immediate postoperative nausea and vomiting. The outcome measures are summarized in Table [3](#TAB3){ref-type="table"}.

###### Primary and secondary outcomes reported in the included studies

  -------------------------------- ------------------------------- -------------- --------------- --------------------------- -------------- ----------------------------- ------------------ ------------------------ --------- ------- -------------------- ------
  Author/Year                      Study Groups                                   Per Group (n)   Primary Outcome (Event/n)                  Secondary Outcome (Event/n)                                                                                      
  Cough                            Sedation                        Laryngospasm                   Hypotension                 Desaturation   Bradycardia                   Nausea/ vomiting   Respiratory depression                                          
  Nishina 1995 \[[@REF2]\]         Saline                                         20              20/20                       Zero           Zero                                             Zero                     Zero      Zero    16/20                Zero
                                   Fentanyl                                       20              19/20                       Zero           Zero                                             Zero                     Zero      Zero    19/20                Zero
                                   Fentanyl                                       20              17/20                       Zero           Zero                                             Zero                     Zero      Zero    19/20                Zero
  Mikawa 1996 \[[@REF12]\]         Saline                                         20              3/20                        NR             Zero                                             Zero                     NR        Zero    NR                   NR
                                   Diltiazem                                      20              3/20                        NR             Zero                                             Zero                     NR        Zero    NR                   NR
                                   Verapamil                                      20              3/20                        NR             Zero                                             Zero                     NR        Zero    NR                   NR
                                   Verapamil                                      20              3/20                        NR             Zero                                             Zero                     NR        Zero    NR                   NR
  Nishina 1997 \[[@REF13]\]        Saline                                         25              25/25                       NR             Zero                                             Zero                     NR        Zero    NR                   NR
                                   Lidocaine                                      25              13/25                       NR             Zero                                             Zero                     NR        Zero    NR                   NR
                                   PG.E                                           25              25/25                       NR             Zero                                             Zero                     NR        Zero    NR                   NR
                                   PG.L                                           25              14/25                       NR             Zero                                             Zero                     NR        Zero    NR                   NR
  Shajar 1999 \[[@REF19]\]         Saline                                         20              11/20                       10/20          NR                                               zero                     NR        Zero    1                    Zero
                                   Remifentanil                                   20              9/20                        3/20           NR                                               zero                     NR        Zero    2                    Zero
  Jee 2002 \[[@REF14]\]            Saline                                                         14/25                       NR             Zero                                             NR                       NR        NR      NR                   NR
                                   Lidocaine                                      25              10/25                       NR             Zero                                             NR                       NR        NR      NR                   NR
                                   Lidocaine                                      25              11/25                       NR             Zero                                             NR                       NR        Non     NR                   NR
  Andrzejowski 2002 \[[@REF17]\]   Saline                                         20              Zero                        NR             NR                                               Zero                     NR        Zero    NR                   NR
                                   Lidocaine                                      20              Zero                        NR             NR                                               Zero                     NR        Zero    NR                   NR
  Guler 2005 \[[@REF15]\]          Dexmedetomidine                                30              3                           NR             Zero                                             3                        Zero      1       NR                   Zero
                                   Saline                                         30              8                           NR             Zero                                             Zero                     Zero      Zero    NR                   Zero
  Turan 2008 \[[@REF25]\]          Saline                                         20              4/20                        NR             Zero                                             Zero                     Zero      Zero    Zero                 Zero
                                   Dexmedetomidine                                20              0/20                        NR             Zero                                             Zero                     Zero      Zero    Zero                 Zero
  Aouad 2009 \[[@REF22]\]          Saline                                         30              0/30                        NR             Zero                                             Zero                     Zero      Zero    NR                   Zero
                                   Remifentanil                                   30              2/30                        NR             Zero                                             Zero                     Zero      Zero    NR                   Zero
  Nho 2009 \[[@REF21]\]            Saline                                         20              8/20                        NR             NR                                               Zero                     Zero      Zero    3/20                 Zero
                                   Remifentanil                                   20              0/20                        NR             NR                                               Zero                     Zero      Zero    0/20                 Zero
  Aksu 2009 \[[@REF3]\]            Dexmedetomidine                                20              1 (5%)                      1              Zero                                             Zero                     Zero      2/20    2/20                 NR
                                   Fentanyl                                       20              4 (20%)                     2              1                                                Zero                     Zero      2/20    3/20                 NR
  Moustafa 2012 \[[@REF20]\]       Lidocaine                                      20              5                           NR             NR                                               Zero                     Zero      Zero    NR                   NR
                                   Dexmedetomidine                                20              14                          NR             NR                                               NR                       Zero      NR      NR                   NR
                                   Dexmedetomidine +Lidocaine                     20              5                           NR             NR                                               NR                       Zero      NR      NR                   NR
  Bindu 2013 \[[@REF29]\]          Saline                                         25              21/25                       5/25           Zero                                             0/25                     Zero      2/25    2/25                 Zero
                                   Dexmedetomidine                                25              4/25                        21/25          Zero                                             2/25                     Zero      13/25   1/25                 Zero
  Mahoori 2014 \[[@REF16]\]        Saline                                         25              11/25                       NR             1                                                Zero                     Zero      Zero    NR                   NR
                                   Remifentanil                                   25              6/25                        NR             Zero                                             Zero                     Zero      Zero    NR                   NR
  Xiaochun 2014 \[[@REF7]\]        Saline                                         30              Zero                        Zero           NR                                               Zero                     Zero      NR      Zero                 NR
                                   Dexmedetomidine                                30              Zero                        Zero           NR                                               Zero                     NR        NR      Zero                 NR
                                   Dexmedetomidine                                30              Zero                        Zero           NR                                               Zero                     NR        NR      Zero                 NR
  Sharma 2014 \[[@REF26]\]         Saline                                         20              2/20                        Zero           Zero                                             Zero                     Zero      0/20    NR                   NR
                                   Lidocaine                                      20              0/20                        Zero           Zero                                             Zero                     Zero      0/20    NR                   NR
                                   Dexmedetomidine                                20              0/20                        Zero           Zero                                             Zero                     Zero      1/20    NR                   NR
  Lee 2014 \[[@REF18]\]            Saline                                         71              14/71                       3              Zero                                             Zero                     Zero      Zero    Zero                 Zero
                                   Dexmedetomidine                                70              5/70                        3              Zero                                             Zero                     Zero      1/70    Zero                 Zero
  Kothari 2014 \[[@REF28]\]        Dexmedetomidine                                25              Zero                        18/25          Zero                                             Zero                     Zero      Zero    NR                   Zero
                                   Lignocaine                                     25              5                           Zero           Zero                                             Zero                     Zero      Zero    NR                   Zero
  Gao 2014 \[[@REF27]\]            Ropivaciane                                    35              0/35                        NR             NR                                               Zero                     Zero      Zero    2/35                 Zero
                                   Diacine                                        35              4/35                        NR             NR                                               Zero                     Zero      Zero    3/35                 Zero
  Qing Fan 2015 \[[@REF23]\]       Sevoflurane-Remifentanil                       25              Zero                        Zero           Zero                                             NR                       Zero      NR      12/25                NR
                                   Sevoflurane-Dexmedetomide SD5                  24              Zero                        Zero           1 (4.2)                                          Zero                     1 (4.2)   NR      4/25                 NR
                                   Sevoflurane-SD7                                25              Zero                        Zero           Zero                                             Zero                     Zero      NR      4/25                 NR
  Kim 2015 \[[@REF6]\]             Saline                                         28(a), 30(b)    NR                          1(a) 6(b)      NR                                               Zero                     NR        Zero    11/28 (a) 3/30 (b)   NR
                                   Dexmedetomidine                                27(a), 30(b)    NR                          13(a) 11(b)    NR                                               Zero                     NR        Zero    9/27 (a) 2/30 (b)    NR
  Mistry 2016 \[[@REF5]\]          Verapamil                                      15              Zero                        Zero           Zero                                             Zero                     NR        Zero    NR                   NR
                                   Dexmedetomidine                                15              Zero                        Zero           Zero                                             Zero                     NR        1/15    NR                   NR
  Shruthi 2016 \[[@REF30]\]        Saline                                         40              12/40                       Zero           Zero                                             0/40                     Zero      0/40    NR                   NR
                                   Dexmedetomidine                                40              2/40                        Zero           Zero                                             9/40                     Zero      2/40    NR                   NR
  Dutta 2016 \[[@REF24]\]          Saline                                         15              Zero                        Zero           Zero                                             Zero                     NR        Zero    NR                   NR
                                   Lidocaine                                      15              Zero                        Zero           Zero                                             Zero                     NR        Zero    NR                   NR
                                   Dexmedetomidine                                15              Zero                        Zero           Zero                                             Zero                     NR        Zero    NR                   NR
  -------------------------------- ------------------------------- -------------- --------------- --------------------------- -------------- ----------------------------- ------------------ ------------------------ --------- ------- -------------------- ------

Cough

Cough was observed in 13 placebo-controlled studies \[[@REF2],[@REF13]-[@REF16],[@REF18]-[@REF19],[@REF21]-[@REF22],[@REF25]-[@REF26],[@REF29]-[@REF30]\], and all these studies were included in the meta-analysis. Overall, cough developed in 23.2% of patients in the intervention group and 42.6% in the control group. The risk of cough was less likely in the intervention group as compared to the control group (OR 0.26, 95% CI 0.15 to 0.46, p=0.00001, I2=35%) (Figure [2](#FIG2){ref-type="fig"}).
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The odds ratio was calculated in the following subgroups.

Local Anesthetics Versus Placebo

Three studies compared lidocaine with placebo and were subjected to a meta-analysis \[[@REF13]-[@REF14],[@REF26]\]. There were 95 patients in each group, 34 developed a cough in the intervention group and 55 in the control group. The odds ratio was found to be 0.33 (95% CI 0.10 - 1.06) p=0.06) I2 =46%.

Alpha Agonist Versus Placebo

Six studies compared the alpha agonist with the placebo \[[@REF15],[@REF18],[@REF25]-[@REF26],[@REF29]-[@REF30]\]. The incidence of cough was significantly reduced with alpha agonists. The odds ratio was 0.16 (95% CI: 0.07, 0.33) p\< 0.00001) I2= 19%.

Opioids Versus Placebo

In five studies, the authors compared opioids with the placebo \[[@REF2],[@REF16],[@REF19],[@REF21]-[@REF22]\]. There was no statistical significance in the incidence of cough \[OR=0.42 95%CI: 0.16, 1.09; p=0.08, I2=24\].

Sedation

Sedation was reported in 13 studies using the Ramsay scale \[[@REF2]-[@REF3],[@REF5]-[@REF7],[@REF18]-[@REF19],[@REF23]-[@REF24],[@REF26],[@REF28]-[@REF30]\]. These studies compared dexmedetomidine with remifentanil, verapamil, fentanyl, and lidocaine.

Alpha Agonists

Dexmedetomidine in different doses was compared to saline in seven studies \[[@REF6]-[@REF7],[@REF15],[@REF18],[@REF25],[@REF29]-[@REF30]\]. The doses used were 0.4 ug/kg \[[@REF6]-[@REF7],[@REF18]\], 0.5 ug/kg \[[@REF15],[@REF25],[@REF30]\], 0.75 ug/kg \[[@REF29]\], and 0.8 ug/kg \[[@REF7]\]. All the authors reported significantly higher sedation in the patient groups who were administered dexmedetomidine. Dexmedetomidine 0.1 ug/kg resulted in a higher degree of sedation as compared to verapamil 0.3 ug/kg \[[@REF5]\], but patients who received verapamil were anxious, agitated, and restless. The results were equivocal in studies that compared dexmedetomidine with lidocaine \[[@REF24],[@REF26]\]. Dexmedetomidine in a dose of 0.3 and 0.5 ug/kg as compared to lidocaine did not show a significant difference in sedation \[[@REF24],[@REF26]\]. Two studies compared dexmedetomidine with opioids \[[@REF3],[@REF23]\]. Dexmedetomidine 0.5 ug/kg was compared with fentanyl 1 ug/kg. One patient in the dexmedetomidine group and two in the fentanyl group were not arousable \[[@REF3]\]. Remifentanil 0.03 ug/kg/min was compared with dexmedetomidine 0.5 ug/kg and 0.7 ug/kg \[[@REF23]\]. Time to awakening was comparable in all the groups p=0.24.

Opioids

Two studies compared opioids with the placebo \[[@REF2],[@REF19]\]. Remifentanil 1 ug/kg was compared with saline. Only three patients were sedated in the remifentanil group as compared to saline where 10 patients had sedation, p=0.056 \[[@REF19]\]. Two doses of fentanyl 1 ug/kg and 2 ug/kg were compared with saline and none of the patients were moderately or severely sedated in any group \[[@REF2]\].

Laryngospasm/ bronchospasm

Laryngospasm/bronchospasm was reported in three studies \[[@REF3],[@REF16],[@REF23]\]. One study looked at the effect of dexmedetomidine 0.5 ug/kg and fentanyl 1 ug/kg before extubation and reported one episode of laryngospasm in the fentanyl group \[[@REF3]\]. Another study compared the effect of remifentanil 0.2 ug/kg with saline and reported one episode of laryngospasm in the saline group \[[@REF16]\]. Two different doses of dexmedetomidine 0.5 and 0.7 ug/kg were compared with remifentanil 0.03 ug/kg/min in another study, resulting in one episode of laryngospasm in the 0.5 ug/kg dexmedetomidine group \[[@REF23]\].

Hypotension

Hypotension was observed in three studies using alpha agonists \[[@REF15],[@REF29]-[@REF30]\]. Fourteen out of 95 patients had hypotension in the intervention group as compared to none in the control group. The odds ratio was 10.47 (CI: 1.86-58.80) with a p-value of 0.008, I2=0% (Figure [3](#FIG3){ref-type="fig"}).

![Comparison of the incidence of hypotension between interventions vs. placebo](cureus-0011-00000006427-i03){#FIG3}

Bradycardia

Five placebo-controlled studies using dexmedetomidine reported on bradycardia at extubation \[[@REF15],[@REF18],[@REF26],[@REF29]-,[@REF30]\]. All reported bradycardia with dexmedetomidine. Eighteen events of bradycardia occurred in the intervention group as compared to two in the control group. The risk of bradycardia was about seven times more likely in the intervention group as compared to the control group \[OR= 6.57; 95% CI: 2.09, 20.64, p=0.001, I2=0%\] (Figure [4](#FIG4){ref-type="fig"}).

![Comparison of the incidence of bradycardia between interventions vs. placebo](cureus-0011-00000006427-i04){#FIG4}

Nausea and vomiting

Five studies reported nausea and vomiting in the immediate postoperative period \[[@REF2],[@REF6],[@REF19],[@REF21],[@REF29]\]. The combined effect was not statistically significant between groups \[OR= 1.03; 95% CI: 0.48, 2.25, p=0.37, I2=8%\] (Figure [5](#FIG5){ref-type="fig"}).

![Comparison of the Incidence of Nausea or Vomiting Between Interventions vs. Placebo](cureus-0011-00000006427-i05){#FIG5}

Subgroup Analysis for Alpha Agonist and Opioid with Control

Nausea and vomiting were observed and reported in two studies using alpha agonists \[[@REF3],[@REF6]\] and three studies with opioids \[[@REF2],[@REF19],[@REF21]\].

In the subgroup analysis, the effect was not statistically significant between groups \[OR= 0.70; 95% CI: 0.29, 1.68, p=0.42, I2=0%\] and \[OR= 1.93; 95% CI: 0.42, 8.90; p=0.40, I2=33%\].

Studies Not Subjected to the Meta-Analysis

Descriptive results

Studies with Local Anesthetics

Ropivacaine 1% was compared with diacine 1% via a transcricoid membrane injection. In the ropivacaine group, 91.9% (95%CI = 85.2-98.7%) patients did not experience any cough versus 46% (95% CI=34.4-59.2%) patients in the diacine group (P\<0.05) \[[@REF27]\].

The efficacy of 2% lidocaine administered through the tracheal tube in attenuating the extubation response in patients who were beta blocked with propranolol 1 mg/kg was compared with placebo, resulting in no difference between lidocaine and placebo in the degree of cough (p-value 0.4) \[[@REF17]\].

Studies with Prostaglandins

Intravenous lidocaine 1 mg /kg, prostaglandin E 0.1 ug/kg, and a combination of lidocaine and prostaglandin E in the same dose were compared with placebo. Cough was reported in 52% of patients treated with lidocaine alone, 56% with lidocaine prostaglandin E combination while in all patients in prostaglandin E group and placebo \[[@REF13]\].

Studies with Alpha Agonists

No patient experienced cough with 0.8 ug/kg dexmedetomidine as compared to 3.3% of patients treated with 0.4 ug/kg dexmedetomidine. This study was in Chinese, and we were not able to get it translated into English; hence, the information presented here is taken from the abstract \[[@REF7]\].

Three studies compared dexmedetomidine with lidocaine \[[@REF24],[@REF26],[@REF28]\], the effect of intravenous dexmedetomidine 0.1 ug/ kg was compared with lidocaine 1 mg/kg or their combination in the same dose \[[@REF20]\]. Twenty-five percent of patients in the dexmedetomidine group and 5% in both the lidocaine and lidocaine with dexmedetomidine groups developed a severe cough.

Dexmedetomidine 0.3 ug/kg was compared with lidocaine 1.5 mg/kg. The number of patients with no cough was 86.6% in the dexmedetomidine group compared to 60% in the lidocaine group (P=0.0087) \[[@REF23]\].

Dexmedetomidine 0.5 ug/kg was compared with lidocaine 1.5 mg/kg. Five patients (20%) had a cough during extubation in the lidocaine group as compared to none in the dexmedetomidine group (p=\<0.05) \[[@REF28]\].

Dexmedetomidine 0.3 ug/kg, when compared with verapamil 0.1 mg/kg, \[[@REF5]\] resulted in 12 (80%) patients in the dexmedetomidine group with no cough while 9 (60 %) in the verapamil group had minimal coughing (P\<0.0029).

Two studies compared dexmedetomidine with remifentanil and fentanyl \[[@REF3],[@REF23]\]. Fan et al. compared two different doses of dexmedetomidine, 0.5 and 0.7 ug/kg, with remifentanil 0.03 ug/kg/min. Only two patients had moderate cough in the remifentanil group, four had moderate, and two had severe cough in the dexmedetomidine 0.5 ug/kg group while none had moderate to severe cough in the dexmedetomidine 0.7 ug/kg group. One patient had laryngospasm in the dexmedetomidine 0.5 group \[[@REF23]\]. Aksu et al. studied the effect of dexmedetomidine 0.5 ug/kg and fentanyl 1 ug/kg. No patient had severe cough in the dexmedetomidine group while four had in the fentanyl group. Only one patient (5%) had moderate cough in the dexmedetomidine group in contrast to four (20%) in the fentanyl group (p= 0.003). One patient developed laryngospasm in the fentanyl group \[[@REF3]\].

Studies with Narcotics

Nho et al. studied the effect of remifentanil infusion maintained at a target organ concentration of 1.5 ng/ml during emergence. Coughing was less frequent in the remifentanil group than in the control group. They did not give the numbers of patients who experienced cough neither the grade of cough \[[@REF21]\].

Studies with Calcium Channel Blockers

Mikawa et al. studied the effect of two different doses of verapamil 0.05 ug/kg and 0.1 ug/kg with diltiazem 0.2 ug/kg and saline. They reported that all patients coughed with the extubation quality scores (median 3, range 2-5) being the same in all the four groups. No patient developed laryngospasm, hypotension, and bradycardia \[[@REF12]\].

Risk of bias across studies

The quality of each study was assessed using the Cochrane risk of bias tool for RCTs \[[@REF27]\]. This information is given in Table [4](#TAB4){ref-type="table"}.

###### Quality assessment of selected studies

  --- -------------------------
      Risk of Bias Assessment
  --- -------------------------

  --------------------------- ------ ---------------------------- ------------------------ ---------------------------------------- -------------------------------- ------------------------- ----------------------------- --------------------
  Study ID                    Year   Random Sequence Generation   Allocation Concealment   Blinding of Participants and Personnel   Blinding of Outcome Assessment   Incomplete Outcome Data   Selective Outcome Reporting   Quality of Studies
  Nishina \[[@REF2]\]         1995   unclear                      low                      low                                      low                              low                       low                           fair
  Mikawa \[[@REF12]\]         1996   low                          low                      low                                      low                              low                       low                           good
  Nishina \[[@REF13]\]        1997   unclear                      unclear                  low                                      unclear                          high                      low                           poor
  Shajar \[[@REF19]\]         1999   low                          low                      low                                      low                              low                       low                           good
  Jee \[[@REF14]\]            2002   high                         unclear                  low                                      low                              low                       low                           fair
  Andrzejowski \[[@REF17]\]   2002   unclear                      low                      low                                      low                              high                      low                           poor
  Guler \[[@REF15]\]          2005   unclear                      low                      low                                      low                              low                       low                           fair
  Turan \[[@REF25]\]          2008   unclear                      low                      low                                      low                              low                       low                           fair
  Aouad \[[@REF22]\]          2009   low                          low                      low                                      low                              low                       low                           good
  Nho \[[@REF21]\]            2009   low                          low                      low                                      low                              low                       low                           good
  Aksu \[[@REF3]\]            2009   unclear                      low                      low                                      low                              low                       low                           fair
  Moustafa \[[@REF20]\]       2012   unclear                      unclear                  low                                      low                              low                       Low                           fair
  Bindu \[[@REF29]\]          2013   low                          unclear                  low                                      low                              low                       low                           fair
  Mahoori \[[@REF16]\]        2014   low                          unclear                  low                                      low                              unclear                   low                           poor
  Zhoo Xiaochun \[[@REF7]\]   2014   low                          low                      low                                      low                              low                       low                           good
  Sharma \[[@REF26]\]         2014   Low                          low                      low                                      low                              low                       low                           good
  Lee \[[@REF18]\]            2014   low                          low                      low                                      low                              low                       low                           good
  Kothari \[[@REF28]\]        2014   Low                          low                      low                                      low                              low                       low                           good
  Gao \[[@REF27]\]            2014   low                          unclear                  low                                      low                              high                      low                           poor
  Qing Fan \[[@REF23]\]       2015   low                          low                      low                                      low                              low                       low                           good
  Kim \[[@REF6]\]             2015   low                          unclear                  low                                      unclear                          low                       Low                           fair
  Mistry \[[@REF5]\]          2016   low                          low                      low                                      low                              low                       low                           good
  Shruthi \[[@REF30]\]        2016   low                          low                      low                                      low                              low                       low                           good
  Dutta \[[@REF24]\]          2016   unclear                      low                      low                                      low                              low                       low                           fair
  --------------------------- ------ ---------------------------- ------------------------ ---------------------------------------- -------------------------------- ------------------------- ----------------------------- --------------------

Discussion
==========

The main findings of this review are that at tracheal extubation, dexmedetomidine significantly reduced the incidence of cough but caused hypotension and bradycardia. Local anesthetics and opioids did not cause hypotension and bradycardia at extubation but their effect on cough was equivocal. Nausea and vomiting were observed with opioids, but this was not statistically significant in comparison to saline. Patients who received dexmedetomidine had a higher Ramsay score in recovery when compared to local anesthetics while the results of opioids on sedation were equivocal.

Tracheal extubation is associated with cardiovascular as well as respiratory complications. Hemodynamic complications, such as hypertension may lead to an increase in intraocular and intracranial pressure, tachycardia, and dysrhythmias \[[@REF12],[@REF28]\]. This can be hazardous in high-risk patients who have hypertension, coronary artery, and /or cerebrovascular disease due to an increase in myocardial oxygen demand, which can lead to further myocardial ischemia and infarction, pulmonary edema, and cerebrovascular hemorrhage \[[@REF4],[@REF6]\]. Various drugs like beta-blockers, calcium channel blockers, vasodilators, lidocaine, and opioids have been used to attenuate this reflex sympathetic stimulation to extubation, with equivocal results and undesirable side effects like sedation, hypotension, bradycardia, nausea, and vomiting \[[@REF26],[@REF29]\]. An ideal agent is the one that keeps blood pressure and heart rate stable and has no undesirable side effects. Hemodynamic response was attenuated significantly by all drugs used in all included studies.

Sedation, respiratory depression, agitation, and nausea and vomiting are not desirable during and after extubation. Excessive sedation can lead to respiratory depression and increases morbidity and length of stay in PACU \[[@REF29]\]. Similarly, agitation in the postoperative period can be very unpleasant for the patient and can lead to hemodynamic compromise. The aim is to have a calm patient with stable hemodynamics in the recovery room.

Extubation can stimulate unwanted airway responses due to laryngeal and tracheal irritation leading to cough, laryngospasm, and bronchospasm. These airway and circulatory responses on extubation can lead to surgical bleeding, cardiovascular instability, and respiratory compromise \[[@REF1]\]. The incidence of post-extubation coughing reported in different studies was between 76% and 96% \[[@REF1],[@REF4],[@REF6]\]. Dexmedetomidine 0.5 ug/kg showed a significant reduction in the incidence of cough after intraocular \[[@REF15]\], intracranial \[[@REF17]\], and spinal surgeries \[[@REF24]\], hence improving the quality of extubation when compared to placebo. It also decreased the need for postoperative analgesia without increasing the duration of stay in recovery \[[@REF21]\]. It may cause bradycardia and hypotension in a dose-dependent manner but without other side effects. The dose of dexmedetomidine most commonly used in studies was 0.5 ug/kg but favorable results were seen with doses as low as 0.3 ug/kg \[[@REF5]\]. Doses higher than 0.5 ug/kg resulted in higher sedation scores when compared to placebo \[[@REF7]\].

Lidocaine alone, given intravenously or intratracheally, failed to produce a favorable outcome on the quality of extubation \[[@REF24],[@REF28]\]. Combination with other drugs, such as prostaglandin E1 and dexmedetomidine, gave better results. Intravenous lidocaine 1 mg/kg, when used in combination with prostaglandin E1, resulted in good-quality extubation with minimal cough or strain \[[@REF13]\]. Laryngotracheal instillation with 2% lidocaine did not produce any difference in the degree of coughing \[[@REF17]\]. Only one study reported the use of 2% lidocaine 1 mg/kg spray down the endotracheal tube, which attenuated the airway circulatory reflexes when compared to lidocaine given intravenously in the same dose \[[@REF14]\]. Dexmedetomidine and lidocaine in combination when administered intravenously resulted in a favorable quality of extubation when compared with dexmedetomidine 0.1 ug/kg alone \[[@REF20]\].

Calcium channel blocker was not found to be effective in the attenuation of cough reflex irrespective of dose and drug used \[[@REF12]\]. Short-acting opioids like remifentanil and fentanyl have been used for the suppression of cough reflex, with remifentanil having more favorable effects. Remifentanil infusion resulted in suppressing the cough reflex better than the placebo \[[@REF21]\]. Remifentanil infusion has also been effectively used to blunt the cough reflexes after thyroidectomies and nasal surgeries \[[@REF21]-[@REF22]\]. When used in patients undergoing abdominal surgery, remifentanil had no significant difference compared to placebo \[[@REF16]\]. This variation can be due to the difference in the type of surgery as well as the use of bolus versus infusion. Fentanyl in a 1 ug/kg dose failed to suppress the cough reflex when compared with 0.5 ug/kg dexmedetomidine \[[@REF3]\]. When given in a dose of 2 ug/kg, fentanyl resulted in a lesser incidence of cough compared to 1 ug/kg but that was not statistically significant \[[@REF2]\]. Nausea and vomiting were not significantly increased with any of the drugs used in the included studies. The majority of the included studies in this review were of good or fair quality with a low risk of bias. Only three studies had one or more criteria for a high risk of bias.

This review has some limitations. First, not all studies were placebo-controlled. There was heterogeneity among the studies (I2 for cough = 60%). Another limitation was that the population included in most studies was the American Society of Anesthesiologists (ASA) I and II. Only three studies included ASA III patients and only one mentioned the associated co-morbidity present in the patients. The results, therefore, may not be extrapolated to patients with co-morbidity who are those actually at risk of having complications. Further work needs to be done with different doses of dexmedetomidine to recommend a dose attenuating the cough reflex but resulting in stable hemodynamics and a calm patient.

Conclusions
===========

This meta-analysis results show that dexmedetomidine 0.4-0.5 ug/kg is associated with good-quality smooth extubation, minimal coughing, no laryngospasm/ bronchospasm, and a calm patient, with stable hemodynamics, without causing respiratory depression, nausea and vomiting, and desaturation. However, in higher doses of more than 0.5 ug/kg, it can cause bradycardia, hypotension, and sedation. More studies are needed to find out the ideal dose to be used for the attenuation of extubation response without causing any untoward circulatory depression. Other pharmacological agents, such as local anesthetics, opioids, and calcium channel blockers, did not attenuate cough.
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PubMed search

(extubation) OR (tracheal extubation) OR (airway extubation) OR (endotracheal extubation) OR (intratracheal extubation)) AND ((beta blocking drug\*) OR (esmolol) OR (labetalol) OR (metoprolol) OR (propranolol) OR (local anesthetic) OR (lidocaine) OR (lignocaine) OR (xylocaine) OR (alpha 2 adrenergic receptor agonists) OR (dexmedetomidine) OR (clonidine) OR (calcium channel blockers) OR (calcium channel antagonist) OR (nicardipine) OR (diltiazem) OR (verapamil) OR (magnesium sulphate)) AND ((cough) OR (dyspnea) OR (apnea) OR (bronchospasm) OR (bronchial spasm) OR (bronchial hyper reactivity) OR (laryngospasm) OR (laryngismus) OR (vocal cord dysfunction) AND (breath holding) OR (propofol) OR (airway obstruction) OR (hypoventilation) OR (hypoxia) OR (hypoxemia) OR (respiratory depression))) AND (Randomized Controlled Trial \[ptyp\] AND (\"1990/01/01\"\[PDAT\]: \"2016/12/31\"\[PDAT\]) AND Humans \[Mesh\] AND adult \[Mesh\]) (77 items)

CINAHL search

Extubation, airway extubation, Esmolol or labetalol or metoprolol, or propranolol, or lidaocaine, or lignocaine, or xylocaine, or dexmedetomidine, or clonidine, or calcium channel antagonist or nicardipine, or diltiazem, or verapamil, or magnesium sulphate, or dyspnea, or bronchospasm, or laryngospasm or vocal cord dysfunction, or propofol or hypoventilation or hypoxemia, or respiratory depression.

 

Cochrane database search

Extubation, airway extubation, Esmolol or labetalol or metoprolol, or propranolol, or lidocaine, or lignocaine, or xylocaine, or dexmedetomidine, or clonidine, or calcium channel antagonist or nicardipine, or diltiazem, or verapamil, or magnesium sulfate, or dyspnea, or bronchospasm, or laryngospasm or vocal cord dysfunction, or propofol or hypoventilation or hypoxemia, or respiratory depression.

Cough

1=no coughing

2=smooth extubation, minimal coughing

3=moderate coughing

4=severe coughing

5=poor extubation, very uncomfortable (laryngospasm and coughing 10 times)

1 and 2 mean no coughing.

3, 4, and 5 are yes.

Sedation score

Ramsay Scale

1=anxious or agitated and restless or both

2=cooperative, oriented and tranquil

3=drowsy but responds to commands

4=asleep and brisk response to light glabella tap or loud auditory stimulus

5=asleep, sluggish response to light glabella tap or loud auditory stimulus

6=asleep and unarguable

1 and 2 mean no sedation.

3, 4, 5, and 6 mean yes.

Laryngospasm/ bronchospasm

1=no spasm

2=spasm present

Respiratory depression: respiratory rate of less than 10 breaths per minute

Bradycardia: heart rate of less than 60 b per minute

Hypotension: blood pressure of less than 20 % of baseline

Nausea/vomiting

1=no nausea / vomiting

2=nausea and vomiting present

Desaturation=oxygen saturation of less than 92% immediately after extubation.

Thresholds for converting the Cochrane risk of bias tool to AHRQ Standards (good, fair, and poor)

Good quality: All criteria met (i.e. low for each domain)

Fair quality: One criterion not met (i.e. high risk of bias for one domain) or two criteria unclear, and the assessment that this was unlikely to have biased the outcome, and there is no known important limitation that could invalidate the results

Poor quality: One criterion not met (i.e. high risk of bias for one domain) or two criteria unclear, and the assessment that this was likely to have biased the outcome, and there are important limitations that could invalidate the results

Poor quality: Two or more criteria listed as high or unclear risk of bias
